Y Intercept Hong Kong Ltd Buys Shares of 48,087 QuidelOrtho Corporation $QDEL

Y Intercept Hong Kong Ltd bought a new position in shares of QuidelOrtho Corporation (NASDAQ:QDEL) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 48,087 shares of the company’s stock, valued at approximately $790,000. Y Intercept Hong Kong Ltd owned 0.07% of QuidelOrtho at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in QDEL. Royal Bank of Canada lifted its holdings in shares of QuidelOrtho by 1,218.7% during the first quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock worth $2,803,000 after purchasing an additional 74,112 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in QuidelOrtho by 10.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after purchasing an additional 21,968 shares during the last quarter. Focus Partners Wealth raised its position in QuidelOrtho by 210.9% during the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after purchasing an additional 13,876 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in QuidelOrtho during the 2nd quarter worth $1,313,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after buying an additional 2,309 shares during the period. 99.00% of the stock is owned by institutional investors.

QuidelOrtho Price Performance

Shares of NASDAQ QDEL opened at $18.27 on Monday. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The firm has a market cap of $1.25 billion, a PE ratio of -1.03 and a beta of 0.69. The company’s fifty day simple moving average is $13.65 and its 200 day simple moving average is $19.48. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same period last year, the firm posted $0.74 earnings per share. The company’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, sell-side analysts forecast that QuidelOrtho Corporation will post 1.87 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on QDEL. UBS Group reissued a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a research note on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $13.62.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.